{"disease":{"id":"benign-prostatic-hyperplasia","name":"Benign prostatic hyperplasia","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":12,"pipeline_drug_count":0,"trial_count":5},"drugs":{"marketed":[{"drug_id":"doxazosin-mesylate","indication_name":"Benign Prostatic Hyperplasia (BPH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOXAZOSIN MESYLATE","company_name":"","drug_phase":"marketed","molecular_target":"alpha 1 adrenoceptor","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Doxazosin selectively blocks alpha 1 adrenoceptors, reducing urethral resistance and systemic vascular resistance."},{"drug_id":"alfuzosin-hydrochloride","indication_name":"Benign Prostatic Hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ALFUZOSIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"alpha 1-adrenoreceptors","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Alfuzosin blocks post-synaptic alpha 1-adrenoreceptors in the prostate and bladder areas to relax smooth muscle."},{"drug_id":"terazosin-hydrochloride","indication_name":"Symptomatic Benign Prostatic Hyperplasia (BPH)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TERAZOSIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"tadalafil","indication_name":"Benign prostatic hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cialis","generic_name":"tadalafil","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 2 group E member 1, Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Potassium voltage-gated channel subfamily H member 2","drug_class":"Phosphodiesterase 5 Inhibitor [EPC]","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"tamsulosin","indication_name":"Benign prostatic hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flomax","generic_name":"tamsulosin","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 7, Alpha-1A adrenergic receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"doxazosin","indication_name":"Benign prostatic hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cardura","generic_name":"DOXAZOSIN","company_name":"Viatris","drug_phase":"marketed","molecular_target":"Alpha-1B adrenergic receptor","drug_class":"alpha-Adrenergic Blocker","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"cialis","indication_name":"Benign prostatic hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cialis","company_name":"Ottawa Hospital Research Institute","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 2 group E member 1, Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Potassium voltage-gated channel subfamily H member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"naftopidil","indication_name":"Benign prostatic hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flivas","generic_name":"NAFTOPIDIL","company_name":"Asahi Kasei","drug_phase":"marketed","molecular_target":"Alpha-1D adrenergic receptor","drug_class":"naftopidil","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"silodosin","indication_name":"Benign prostatic hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rapaflo","generic_name":"SILODOSIN","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"alpha-1 adrenoreceptors","drug_class":"alpha-Adrenergic Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Silodosin blocks alpha-1 adrenoreceptors in the prostate and bladder, causing smooth muscle relaxation and improving urine flow."},{"drug_id":"terazosin","indication_name":"Benign prostatic hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Hytrin","generic_name":"TERAZOSIN","company_name":"","drug_phase":"marketed","molecular_target":"Alpha-1D adrenergic receptor","drug_class":"alpha-Adrenergic Blocker","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"alfuzosin","indication_name":"Benign prostatic hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Uroxatral","generic_name":"ALFUZOSIN","company_name":"Advanz","drug_phase":"marketed","molecular_target":"alpha 1-adrenoreceptors","drug_class":"alpha-Adrenergic Blocker","quality_score":10,"revenue":null,"mechanism":"Alfuzosin blocks post-synaptic alpha 1-adrenoreceptors in the prostate and bladder areas to relax smooth muscle."},{"drug_id":"terazosine","indication_name":"Benign prostatic hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Terazosine","company_name":"University of Iowa","drug_phase":"phase_2","molecular_target":"Ribosyldihydronicotinamide dehydrogenase [quinone], Solute carrier family 22 member 1, 5-hydroxytryptamine receptor 2A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"avodart","indication_name":"Benign prostatic hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avodart","company_name":"GlaxoSmithKline","drug_phase":"marketed","molecular_target":"3-oxo-5-alpha-steroid 4-dehydrogenase 1, 3-oxo-5-alpha-steroid 4-dehydrogenase 2, Glycine receptor subunit alpha-1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"dutasteride","indication_name":"Benign prostatic hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avodart","generic_name":"dutasteride","company_name":"GSK (GlaxoSmithKline)","drug_phase":"marketed","molecular_target":"3-oxo-5-alpha-steroid 4-dehydrogenase 1, 3-oxo-5-alpha-steroid 4-dehydrogenase 2, Glycine receptor subunit alpha-1","drug_class":"5-alpha-reductase inhibitor (dual)","quality_score":null,"revenue":null,"mechanism":"Dual 5-alpha-reductase inhibitor (types I and II) that more completely suppresses DHT than finasteride for BPH treatment."},{"drug_id":"finasteride","indication_name":"Benign prostatic hyperplasia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Propecia","generic_name":"finasteride","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1, Cytochrome P450 2C19, Cytochrome P450 2C9","drug_class":"5-alpha-reductase inhibitor","quality_score":null,"revenue":null,"mechanism":"Selective type II 5-alpha-reductase inhibitor that blocks conversion of testosterone to dihydrotestosterone (DHT), treating BPH and male pattern hair loss."}],"pipeline":[],"offLabel":[],"totalMarketed":15,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07159165","title":"Registry of MIUS for Benign Prostatic Obstruction","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":10000,"lead_sponsor_name":"Ondokuz Mayıs University","has_results":false},{"nct_id":"NCT06182189","title":"Protocollo N 2014 - Benign Prostatic Hyperplasia","phase":"","overall_status":"RECRUITING","enrollment_count":8000,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT05422677","title":"An Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia","phase":"","overall_status":"COMPLETED","enrollment_count":4698,"lead_sponsor_name":"Hanmi Pharmaceutical Company Limited","has_results":false},{"nct_id":"NCT05292235","title":"Perioperative Parameter and Treatment Outcomes of Surgical Treatment for Benign Prostate Hyperplasia in Hong Kong","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT07242807","title":"Minimally Invasive Prostate Interventions Registry (MIST Study)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Necmettin Erbakan University","has_results":false},{"nct_id":"NCT06589154","title":"The Application of Multimodal Artificial Intelligence Systems in Prostate Cancer Diagnosis and Prognosis Analysis","phase":"","overall_status":"COMPLETED","enrollment_count":1651,"lead_sponsor_name":"Shanghai Changzheng Hospital","has_results":false},{"nct_id":"NCT04726748","title":"Economic Evaluation of Prostatic Urethral Lift","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1360,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT01018511","title":"Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1334,"lead_sponsor_name":"Astellas Pharma Europe B.V.","has_results":true},{"nct_id":"NCT04831476","title":"Α Prospective Observational Study for the Evaluation of Disease Control and Quality of Life in Patients With Benign PROStatic hyPERplasia Under Fixed Dose combΙnaTion Treatment With Dutasteride and Tamsulosin . PROSPERITY Group of Studies (I&II)","phase":"","overall_status":"COMPLETED","enrollment_count":1296,"lead_sponsor_name":"Elpen Pharmaceutical Co. Inc.","has_results":false},{"nct_id":"NCT01021332","title":"Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1067,"lead_sponsor_name":"Astellas Pharma Europe B.V.","has_results":true},{"nct_id":"NCT06546735","title":"Efficacy and Safety of Two Fixed-dose Combinations in Men with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. (BENIPRO)","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":816,"lead_sponsor_name":"Eurofarma Laboratorios S.A.","has_results":false},{"nct_id":"NCT02972268","title":"Clinical Trial to Compare the Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for LUTS Due to BPH","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":780,"lead_sponsor_name":"Jeil Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT02757768","title":"A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":715,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT03479359","title":"Learning Curve of Digital Rectal Examination for Prostate Cancer Among Internship","phase":"","overall_status":"UNKNOWN","enrollment_count":700,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT04947631","title":"Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":667,"lead_sponsor_name":"Dongkook Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03179670","title":"Interest of a Systematic Assessment of the Treatment of LUTS in the Management of BPH","phase":"","overall_status":"COMPLETED","enrollment_count":625,"lead_sponsor_name":"RECORDATI GROUP","has_results":false},{"nct_id":"NCT00127179","title":"A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":600,"lead_sponsor_name":"Organon and Co","has_results":false},{"nct_id":"NCT06852859","title":"Patient-reported Pain and Symptom Relief During Three Months After Surgery for Benign Prostatic Hyperplasia","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Sahlgrenska University Hospital","has_results":false},{"nct_id":"NCT06560476","title":"OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Urotronic Inc.","has_results":false},{"nct_id":"NCT03521648","title":"Database for the Assessment of Efficacy and Safety of BPH Treatment","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Dominik Abt","has_results":false},{"nct_id":"NCT07357714","title":"Urinary Function and Multimorbidity Risks: A Longitudinal Study in Beijing Community-Dwelling Elderly","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT03527589","title":"Embosphere® PROstate Post Market Study","phase":"","overall_status":"COMPLETED","enrollment_count":499,"lead_sponsor_name":"Merit Medical Systems, Inc.","has_results":true},{"nct_id":"NCT06528613","title":"Real World Study in Greek Patients with BPH for Disease Control and QoL Under FDC Treatment with Solifenacin/Tamsulosin.","phase":"","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Elpen Pharmaceutical Co. Inc.","has_results":false},{"nct_id":"NCT04032067","title":"Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":423,"lead_sponsor_name":"GemVax & Kael","has_results":false},{"nct_id":"NCT04648176","title":"Application of MOSES Technology in BPH","phase":"NA","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Hospital Universitari Vall d'Hebron Research Institute","has_results":false},{"nct_id":"NCT03297281","title":"Stop or Ongoing Oral Anticoagulation in Patients Undergoing Pvp (SOAP)","phase":"NA","overall_status":"RECRUITING","enrollment_count":389,"lead_sponsor_name":"Clinique Pasteur","has_results":false},{"nct_id":"NCT06380062","title":"Choline Metabolites in People With Prostate Cancer and Those With Benign Hyperplasia","phase":"","overall_status":"COMPLETED","enrollment_count":350,"lead_sponsor_name":"Universität des Saarlandes","has_results":false},{"nct_id":"NCT05574244","title":"Comparison of Functional Outcomes of Ejaculation-preserving Partial Trans Urethral Resection of the Prostate With Complete Trans Urethral Resection of the Prostate for Benign Prostatic Obstruction","phase":"NA","overall_status":"RECRUITING","enrollment_count":336,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT05116592","title":"The Risk Factor and Outcome of Transient Incontinence After Prostate Enucleation Surgery","phase":"","overall_status":"UNKNOWN","enrollment_count":330,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT01107392","title":"Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":315,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT05551221","title":"The Efficacy and Safety of Silodosin Singly or Combined With Ningmitai Capsules in the Treatment of Benign Prostatic Hyperplasia","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":312,"lead_sponsor_name":"Xintian Pharmaceutical","has_results":false},{"nct_id":"NCT05585450","title":"Effect of Electroacupuncture on Benign Prostatic Hyperplasia","phase":"NA","overall_status":"RECRUITING","enrollment_count":306,"lead_sponsor_name":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","has_results":false},{"nct_id":"NCT06656689","title":"Study on Water Vapor Thermal Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Saint Vincent's Hospital, Korea","has_results":false},{"nct_id":"NCT04185441","title":"Efficacy and Safety of Tanzânia Association in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":295,"lead_sponsor_name":"EMS","has_results":false},{"nct_id":"NCT03157726","title":"Transurethral Plasmakinetic Enucleation of Prostate Versus Transurethral Resection of Prostate","phase":"NA","overall_status":"UNKNOWN","enrollment_count":294,"lead_sponsor_name":"Zhujiang Hospital","has_results":false},{"nct_id":"NCT07144709","title":"A 6-months Observational Study to Evaluate the Quality of Life of Patients Treated With Phytotherapy or Alpha-blockers for Benign Prostatic Hyperplasia","phase":"","overall_status":"COMPLETED","enrollment_count":288,"lead_sponsor_name":"Pierre Fabre Medicament","has_results":false},{"nct_id":"NCT03583034","title":"Outcomes and Complications of Holmium Laser Enucleation of the Prostate in Expert Hands","phase":"","overall_status":"UNKNOWN","enrollment_count":275,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT04446429","title":"Anti-Androgen Treatment for COVID-19","phase":"NA","overall_status":"COMPLETED","enrollment_count":268,"lead_sponsor_name":"Applied Biology, Inc.","has_results":true},{"nct_id":"NCT07016776","title":"Uroflowmetry Curve Types and IPSS in Men With LUTS","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":250,"lead_sponsor_name":"Tarik Emre Sener","has_results":false},{"nct_id":"NCT06181175","title":"Treatment of BPH With CO2 Serenoa +PEA as Monotherapy or in Combination With Tamsulosin: ProSeRePEA Trial","phase":"NA","overall_status":"UNKNOWN","enrollment_count":250,"lead_sponsor_name":"Azienda Ospedaliero Universitaria Maggiore della Carita","has_results":false},{"nct_id":"NCT05341661","title":"Butterfly Pivotal Study","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":245,"lead_sponsor_name":"Butterfly Medical Ltd.","has_results":false},{"nct_id":"NCT06944145","title":"New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":242,"lead_sponsor_name":"Beth Israel Deaconess Medical Center","has_results":false},{"nct_id":"NCT07510685","title":"Closed-System Bladder Irrigation to Reduce Urinary Tract Infections After Endoscopic Urologic Surgery (IRIS Trial)","phase":"NA","overall_status":"COMPLETED","enrollment_count":240,"lead_sponsor_name":"University of Pisa","has_results":false},{"nct_id":"NCT06849258","title":"A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms","phase":"NA","overall_status":"RECRUITING","enrollment_count":215,"lead_sponsor_name":"Rivermark Medical","has_results":false},{"nct_id":"NCT04757116","title":"Post-Market Study to Assess iTind Safety in Comparison to UroLift","phase":"NA","overall_status":"RECRUITING","enrollment_count":206,"lead_sponsor_name":"Olympus Corporation of the Americas","has_results":false},{"nct_id":"NCT05027971","title":"Flexiva Pulse Registry","phase":"","overall_status":"COMPLETED","enrollment_count":201,"lead_sponsor_name":"Boston Scientific Corporation","has_results":true},{"nct_id":"NCT03075449","title":"Real World Data on Management of Male LUTS","phase":"","overall_status":"COMPLETED","enrollment_count":201,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT07277556","title":"TURP Outcome Prediction Calculator Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"General Hospital Sveti Duh","has_results":false},{"nct_id":"NCT05678452","title":"Comparative Study Between Safety and Effectiveness of High Versus Low Power HOLEP","phase":"NA","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Al-Azhar University","has_results":false},{"nct_id":"NCT04352257","title":"Bladder and Prostate Sonomorphology in Patients With Symptomatic Benign Prostatic Hyperplasia","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Kafrelsheikh University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}